← Back to Clinical Trials
Recruiting NCT06671457

NCT06671457 Model-Driven Individualized Transcranial Direct Current Stimulation for the Treatment of Insomnia Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06671457
Status Recruiting
Phase
Sponsor Zhen Wang
Condition Insomnia
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-11-10
Primary Completion 2026-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Active transcranial direct current stimulationSham transcranial direct current stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-11-10 with a primary completion date of 2026-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is designed to evaluate the efficacy and to explore the best individualized stimulus paradigm of transcranial Electrical Stimulation for insomnia patients.

Eligibility Criteria

Inclusion Criteria: 1. Age between 18 and 65 years; 2. Meets the diagnostic criteria for insomnia disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 3. Has not taken psychiatric medications in the 8 weeks prior to enrollment or has been on stable psychiatric medication for 8 weeks (excluding benzodiazepines); 4. Insomnia severity as indicated by an ISI score \> 10; 5. Minimum education level of junior high school or above. Exclusion Criteria: 1. Past or current diagnosis of disorders other than insomnia disorder, anxiety disorder, or depressive disorder according to DSM-5; 2. Currently using benzodiazepines as sleep aids; 3. Moderate to severe anxiety or depression (HAMD-17 score \> 16 or HAMA score \> 24); 4. Patients with obstructive sleep apnea syndrome; 5. Previous treatment with ECT, rTMS, tES, or cognitive behavioral therapy for insomnia disorder; 6. Severe physical illnesses or any condition that may induce seizures or intracranial hypertension, including cardiovascular or respiratory diseases; 7. History of neurological disorders (e.g., epilepsy, cerebrovascular accidents) or history of brain injury or brain surgery; 8. Presence of implantable medical devices such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants; 9. Severe negative thoughts or high suicide risk; 10. Pregnant or planning to conceive in the near future.

Contact & Investigator

Central Contact

Zhen Wang, PhD,MD

✉ wangzhen@smhc.org.cn

📞 +86 34773516

Principal Investigator

Zhen Wang, PhD,MD

PRINCIPAL INVESTIGATOR

Shanghai Mental Health Center

Frequently Asked Questions

Who can join the NCT06671457 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Insomnia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06671457 currently recruiting?

Yes, NCT06671457 is actively recruiting participants. Contact the research team at wangzhen@smhc.org.cn for enrollment information.

Where is the NCT06671457 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT06671457 clinical trial?

NCT06671457 is sponsored by Zhen Wang. The principal investigator is Zhen Wang, PhD,MD at Shanghai Mental Health Center. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology